Resistant hypertension is a common clinical problem faced by both primary care clinicians
and specialists. While the exact prevalence of resistant hypertension is unknown, clinical …

ContextHypertension is a leading cause of end-stage renal disease (ESRD) in the United
States, with no known treatment to prevent progressive declines leading to ESRD.ObjectiveTo …

ContextIncidence of end-stage renal disease due to hypertension has increased in recent
decades, but the optimal strategy for treatment of hypertension to prevent renal failure is …

Background. Hypertension is a frequent complication of chronic renal failure, but its causes
are not fully understood. There is indirect evidence that increased activity of the sympathetic …

Background In observational studies, the relationship between blood pressure and end-stage
renal disease (ESRD) is direct and progressive. The burden of hypertension-related …

Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior
trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have …

Background Although inhibitors of the renin–angiotensin–aldosterone system can slow the
progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (…

Background Chronic kidney disease (CKD) associated with type 2 diabetes is the leading
cause of kidney failure, with both inflammation and oxidative stress contributing to disease …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, …

Understanding kidney disease relies on defining the complexity of cell types and states, their
associated molecular profiles and interactions within tissue neighbourhoods 1 . Here we …